OpenAlex
PricingAboutJobs
Log inGet started
Work

Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.

PubMed

Year: 2014
Type: article
Study design: Clinical Trial
Source: PubMed
Authors: Shigeyoshi Iwamoto, Shoichi Hazama, Takeshi Kato, Yasuhiro Miyake, Mutsumi Fukunaga, Chu Matsuda, Hiroyuki Bando, Junichi Sakamoto, Koji Oba, Hideyuki Mishima
Institutions: Kansai Medical University, Kansai Medical University Medical Center, Yamaguchi University, Kansai Rosai Hospital, Nishinomiya Municipal Central Hospital, Sakai City Medical Center, Osaka Prefectural Medical Center, Tokai Central Hospital, Hokkaido University Hospital, Aichi Medical University Hospital
Language: English

Topic: Colorectal Cancer Treatments and Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: cetuximab, FOLFIRI, metastatic colorectal cancer, KRAS wild-type, second-line therapy, EGFR inhibition, BRAF mutation, PIK3CA mutation, response rate, progression-free survival, overall survival, adverse events, leukopenia, neutropenia
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2115594109
FWCI: 2.087
Cites: 27
Cited by: 25
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security